

Toshio Takagi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8030993/publications.pdf>

Version: 2024-02-01

100
papers

1,415
citations

394421

19
h-index

434195

31
g-index

101
all docs

101
docs citations

101
times ranked

1797
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgical outcomes of robot-assisted laparoscopic partial nephrectomy for cystic renal cell carcinoma. <i>Journal of Robotic Surgery</i> , 2022, 16, 649-654.	1.8	3
2	Validation of a Predictive Model for New Baseline Renal Function After Radical Nephrectomy or Robot-Assisted Partial Nephrectomy in Japanese Patients. <i>Journal of Endourology</i> , 2022, 36, 745-751.	2.1	2
3	Efficacy and feasibility of robot-assisted partial nephrectomy for octogenarians: comparison with younger counterparts. <i>Journal of Robotic Surgery</i> , 2022, 16, 1165-1173.	1.8	4
4	Surgical outcomes for older patients with renal cell carcinoma and inferior vena cava thrombus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 110.e11-110.e18.	1.6	2
5	Comparison of surgical outcomes after robot-assisted laparoscopic partial nephrectomy between patients continuing and discontinuing aspirin therapy: a Japanese single-centre study. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	1.3	0
6	C-reactive protein kinetics to predict recurrence of high-risk renal cell carcinoma after radical surgery. <i>International Journal of Clinical Oncology</i> , 2022, 27, 969-976.	2.2	2
7	“Thrombus-first” or “thrombus-last” approach for surgical management of renal cell carcinoma with inferior vena cava thrombus. <i>International Journal of Urology</i> , 2022, , .	1.0	0
8	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	1.3	0
9	New Longitudinal Component of the RENAL Nephrometry Score for Predicting the Operative Complexity in Transperitoneal Robot-Assisted Partial Nephrectomy. <i>Journal of Endourology</i> , 2022, 36, 762-769.	2.1	5
10	A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma. <i>IJU Case Reports</i> , 2022, 5, 126-128.	0.3	1
11	Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era. <i>Targeted Oncology</i> , 2022, 17, 307-319.	3.6	4
12	Perioperative outcomes following robot-assisted partial nephrectomy for renal cell carcinoma according to surgeon generation. <i>BMC Surgery</i> , 2022, 22, .	1.3	0
13	Editorial Comment from Dr Ishihara <i>et al.</i> to Nomogram for predicting survival of renal cell carcinoma with tumor thrombus based on perioperative clinicopathological factors from a Chinese high-volume center. <i>International Journal of Urology</i> , 2022, 29, 993-994.	1.0	0
14	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria. <i>Targeted Oncology</i> , 2022, 17, 475-482.	3.6	4
15	Comparisons of surgical outcomes between transperitoneal and retroperitoneal approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: a propensity score-matched comparative analysis. <i>Journal of Robotic Surgery</i> , 2021, 15, 99-104.	1.8	20
16	Comparison of postoperative recovery after robot-assisted partial nephrectomy of T1 renal tumors through retroperitoneal or transperitoneal approach: A Japanese single institutional analysis. <i>International Journal of Urology</i> , 2021, 28, 183-188.	1.0	12
17	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 646-653.	1.3	22
18	Predictive role of $\hat{\gamma}$ -glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 552-561.	2.2	7

#	ARTICLE	IF	CITATIONS
19	Efficacy of nivolumab versus molecularly targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions. <i>International Journal of Urology</i> , 2021, 28, 99-106.	1.0	4
20	Editorial Comment to Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone. <i>IJU Case Reports</i> , 2021, 4, 25-25.	0.3	0
21	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 77.e17-77.e25.	1.6	16
22	Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma. <i>In Vivo</i> , 2021, 35, 2855-2862.	1.3	6
23	Therapeutic benefit of lymphadenectomy for older patients with urothelial carcinoma of the upper urinary tract: a propensity score matching study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 802-809.	1.3	3
24	Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 674-682.	1.6	2
25	Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 819-825.	1.3	11
26	Greater Renal Function Benefit from Enucleation Technique for More Complex Renal Tumors in Robot-Assisted Partial Nephrectomy. <i>Journal of Endourology</i> , 2021, 35, 1512-1519.	2.1	4
27	Robot-Assisted Laparoscopic Partial Nephrectomy for Allograft Renal Cell Carcinoma: A Case Report. <i>Transplantation Proceedings</i> , 2021, 53, 1445-1449.	0.6	0
28	Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study. <i>Targeted Oncology</i> , 2021, 16, 493-502.	3.6	6
29	Comparison of Surgical Outcomes Between Enucleation and Standard Resection in Robot-Assisted Partial Nephrectomy for Completely Endophytic Renal Tumors Through a 1:1 Propensity Score-Matched Analysis. <i>Journal of Endourology</i> , 2021, 35, 1779-1784.	2.1	9
30	Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study. <i>International Journal of Urology</i> , 2021, 28, 1075-1076.	1.0	3
31	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1751-1756.	1.3	7
32	Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1744-1750.	1.3	2
33	Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. <i>Pathology</i> , 2021, 53, 720-727.	0.6	8
34	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 735.e9-735.e16.	1.6	15
35	Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoing robot-assisted partial nephrectomy using enhanced MDCT. <i>Scientific Reports</i> , 2021, 11, 2245.	3.3	7
36	Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma. <i>In Vivo</i> , 2021, 35, 3585-3589.	1.3	4

#	ARTICLE	IF	CITATIONS
37	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, , .	1.9	6
38	Association between Ureteral Clamping Time and Acute Kidney Injury during Robot-Assisted Radical Cystectomy. <i>Current Oncology</i> , 2021, 28, 4986-4997.	2.2	4
39	Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). <i>World Journal of Urology</i> , 2020, 38, 151-158.	2.2	23
40	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 705-712.	2.2	3
41	The De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Prognosticator in Patients With End-stage Renal Disease-associated Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 236-240.e1.	1.9	12
42	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 526-532.	1.6	18
43	Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma. <i>In Vivo</i> , 2020, 34, 1541-1546.	1.3	10
44	Lower Incidence of Postoperative Acute Kidney Injury in Robot-Assisted Partial Nephrectomy Than in Open Partial Nephrectomy: A Propensity Score-Matched Study. <i>Journal of Endourology</i> , 2020, 34, 754-762.	2.1	13
45	Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 515-520.	1.6	15
46	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy of a solitary kidney. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1155-1162.	2.2	10
47	Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors. <i>IJU Case Reports</i> , 2020, 3, 25-27.	0.3	11
48	Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution. <i>International Journal of Clinical Oncology</i> , 2020, 25, 892-898.	2.2	16
49	Computed tomography imaging characteristics of clear cell papillary renal cell carcinoma. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 26-33.	1.5	6
50	Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2019, 14, 453-463.	3.6	53
51	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. <i>Medical Oncology</i> , 2019, 36, 35.	2.5	4
52	Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 576-580.	1.3	11
53	Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy. <i>Targeted Oncology</i> , 2019, 14, 179-186.	3.6	14
54	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 355.e21-355.e29.	1.6	64

#	ARTICLE	IF	CITATIONS
55	Peritumoral pseudocapsule status according to pathological characteristics from robot-assisted laparoscopic partial nephrectomy for localized renal cell carcinoma. <i>International Journal of Urology</i> , 2019, 26, 446-450.	1.0	13
56	Robot-assisted laparoscopic partial nephrectomy versus laparoscopic partial nephrectomy: A propensity score-matched comparative analysis of surgical outcomes and preserved renal parenchymal volume. <i>International Journal of Urology</i> , 2018, 25, 359-364.	1.0	21
57	Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. <i>International Journal of Clinical Oncology</i> , 2018, 23, 559-567.	2.2	11
58	Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy. <i>International Journal of Clinical Oncology</i> , 2018, 23, 539-546.	2.2	13
59	Comparison of Kidney Function in the Early Postoperative Period in Transperitoneal Robot-Assisted Laparoscopic Partial Nephrectomy Between Anterior and Posterior Renal Tumors: A Propensity Score-Matched Study. <i>Journal of Endourology</i> , 2018, 32, 111-115.	2.1	10
60	Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 745-755.	3.6	14
61	Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multi-institutional study. <i>Pathology International</i> , 2018, 68, 543-549.	1.3	37
62	Comparison of perioperative outcomes with or without renorrhaphy during open partial nephrectomy: A propensity score-matched analysis. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2018, 44, 467-474.	1.5	15
63	Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 379-387.	3.6	4
64	Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 860-863.	1.3	14
65	Impact of the Mayo Adhesive Probability Score on the Complexity of Robot-Assisted Partial Nephrectomy. <i>Journal of Endourology</i> , 2018, 32, 928-933.	2.1	23
66	Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 226-232.	1.3	8
67	Surgical and Oncologic Outcomes of Laparoscopic Radical Nephrectomy for Non-Metastatic Renal Cancer in Long-Term Dialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2017, 21, 31-37.	0.9	1
68	Differences in Clinical and Pathological Features of Renal Cell Carcinoma Between Japanese Patients After Kidney Transplantation and Those on Hemodialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2017, 21, 133-138.	0.9	4
69	Robot-assisted laparoscopic versus open partial nephrectomy in patients with chronic kidney disease: A propensity score-matched comparative analysis of surgical outcomes. <i>International Journal of Urology</i> , 2017, 24, 505-510.	1.0	24
70	Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 598-604.	1.9	27
71	Comparison of Surgical Outcomes Between Resection and Enucleation in Robot-Assisted Laparoscopic Partial Nephrectomy for Renal Tumors According to the Surface-Intermediate-Base Margin Score: A Propensity Score-Matched Study. <i>Journal of Endourology</i> , 2017, 31, 756-761.	2.1	20
72	Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 495-501.	1.9	22

#	ARTICLE	IF	CITATIONS
73	Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 542.e1-542.e9.	1.6	21
74	Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study. <i>International Journal of Clinical Oncology</i> , 2017, 22, 136-144.	2.2	42
75	Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment. <i>Targeted Oncology</i> , 2016, 11, 605-617.	3.6	66
76	Comparison of progression to end-stage renal disease requiring dialysis after partial or radical nephrectomy for renal cell carcinoma in patients with severe chronic kidney disease. <i>International Urology and Nephrology</i> , 2016, 48, 1421-1427.	1.4	15
77	Comparison of survival rates in stage 1 renal cell carcinoma between partial nephrectomy and radical nephrectomy patients according to age distribution: a propensity score matching study. <i>BJU International</i> , 2016, 117, E52-9.	2.5	13
78	A propensity score-matched comparison of surgical precision obtained by using volumetric analysis between robot-assisted laparoscopic and open partial nephrectomy for T1 renal cell carcinoma: a retrospective non-randomized observational study of initial outcomes. <i>International Urology and Nephrology</i> , 2016, 48, 1585-1591.	1.4	17
79	Editorial Comment to Practical <i>in vivo</i> evaluation of application of surgical clips to sutures during reapproximation of renal tissue in partial nephrectomy. <i>International Journal of Urology</i> , 2016, 23, 960-961.	1.0	0
80	The safety and validity of surgical resection for hemodialysis-dependent patients with renal cell carcinomas involving the inferior vena cava. <i>International Cancer Conference Journal</i> , 2016, 5, 136-139.	0.5	0
81	Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. <i>International Journal of Clinical Oncology</i> , 2016, 21, 126-132.	2.2	18
82	Early unclamping might reduce the risk of renal artery pseudoaneurysm after robot-assisted laparoscopic partial nephrectomy. <i>International Journal of Urology</i> , 2015, 22, 1096-1102.	1.0	54
83	Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1035-1041.	2.2	18
84	Fat-poor angiomyolipoma with cyst-like changes mimicking a cystic renal cell carcinoma: a case report. <i>World Journal of Surgical Oncology</i> , 2015, 13, 251.	1.9	5
85	Analysis of Atrophy After Clamped Partial Nephrectomy and Potential Impact of Ischemia. <i>Urology</i> , 2015, 85, 1417-1423.	1.0	16
86	Early Postoperative Screening by Contrast-Enhanced CT and Prophylactic Embolization of Detected Pseudoaneurysms Prevents Delayed Hemorrhage after Partial Nephrectomy. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 950-957.	0.5	16
87	Renal sinus exposure as an independent factor predicting asymptomatic unruptured pseudoaneurysm formation detected in the early postoperative period after minimally invasive partial nephrectomy. <i>International Journal of Urology</i> , 2015, 22, 356-361.	1.0	33
88	Assessment of Surgical Outcomes of the Non-renalorrhaphy Technique in Open Partial Nephrectomy for T1b Renal Tumors. <i>Urology</i> , 2015, 86, 529-533.	1.0	23
89	Multicenter Validation of Surgeon Assessment of Renal Preservation in Comparison to Measurement With 3D Image Analysis. <i>Urology</i> , 2015, 86, 534-538.	1.0	17
90	Therapeutic role of template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract. <i>World Journal of Clinical Oncology</i> , 2015, 6, 237.	2.3	18

#	ARTICLE	IF	CITATIONS
91	Better recovery of kidney function in patients with de novo chronic kidney disease after partial nephrectomy compared with those with pre-existing chronic kidney disease. International Journal of Urology, 2014, 21, 613-616.	1.0	8
92	Enhanced computed tomography after partial nephrectomy in early postoperative period to detect asymptomatic renal artery pseudoaneurysm. International Journal of Urology, 2014, 21, 880-885.	1.0	49
93	Chronic Kidney Disease Due to Surgical Removal of Nephrons: Relative Rates of Progression and Survival. Journal of Urology, 2014, 192, 1057-1063.	0.4	119
94	Assessment of Outcomes in Partial Nephrectomy Incorporating Detailed Functional Analysis. Urology, 2014, 84, 1128-1133.	1.0	6
95	Poorly Functioning Kidneys Recover from Ischemia after Partial Nephrectomy as Well as Strongly Functioning Kidneys. Journal of Urology, 2014, 192, 665-670.	0.4	44
96	Editorial Comment. Urology, 2014, 84, 334.	1.0	0
97	Editorial Comment. Urology, 2014, 84, 332-333.	1.0	0
98	Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: Single-center experience. International Journal of Urology, 2013, 20, 1072-1077.	1.0	19
99	Prognosis and characteristics of renal cell carcinoma in hemodialysis patients: Bilateral occurrence does not influence cancer-specific survival. International Journal of Urology, 2011, 18, 806-812.	1.0	8
100	Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Japanese Journal of Clinical Oncology, 0, , .	1.3	1